Since the sequences of this novel fusion peptide immunogen (MSLN-PDL1-GMCSF) are originated from human, it is important to test this novel human MSLN-PDL1-GMCSF vaccine in cancer patients to determine whether anti-PD-L1 antibody and CTL responses can be induced and whether the PD-L1-containing MSLN vaccine is safe. Here, MSLN is linked to cancer.